Search Results for “EU” – Page 384 – media

Black Death and incurable Marburg Virus now spreading across Africa’s cities

Africa is currently contending with two serious disease outbreaks. The pneumonic plague has been making headlines as it sweeps across Madagascar, but there are concerns about it are being eclipsed by a far more sinister threat: A rare and fatal virus known Marburg virus disease (MVD), which has now broken out in Uganda.
- Source: naturalnews
- 1,128
- November 8, 2017
Market Views MVD pneumonic plague WHO
Merck, Pfizer launch Bavencio for rare skin cancer

Merck and Pfizer have launched in the UK of Bavencio, the first medicine to be licensed for the treatment of the rare, aggressive skin cancer of metastatic Merkel Cell Carcinoma (mMCC).
- Source: Pharmatimes
- 488
- November 7, 2017
avelumab Company Insight mMCC skin cancer
Moderna Announces New Collaboration with AstraZeneca

Moderna Therapeutics today announced a new license and collaboration with AstraZeneca to co-develop and co-commercialize a messenger RNA (mRNA) therapeutic encoding for Relaxin. The companies will advance the new Relaxin development candidate, AZD7970, toward the clinic as an investigational treatment for heart failure.
- Source: Modernatx
- 465
- November 7, 2017
heart Market Views mRNA
Scientists discover potential treatment to stop glaucoma in its tracks

Vision scientists at the University of California, Berkeley, and the University of Toronto have discovered that naturally occurring molecules known as lipid mediators have the potential to halt the progression of glaucoma, the world's second-leading cause of blindness.
- Source: Medicalxpress
- 492
- November 7, 2017
glaucoma lipid mediators neurodegenerative disease
‘Precision Medicine’ may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the world's more diverse populations, according to a study led by the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, and the Keck School of Medicine of the University of Southern California (USC).
- Source: worldpharmanews
- 551
- November 6, 2017
cancer oncology precision medicine Researches
Merck subsidiary StayWell acquires app maker MedHelp for undisclosed sum

To expedite its push into mobile health, Yardley, Pennsylvania-based StayWell announced today that it has acquired the mobile health portion of Silicon Valley-based MedHelp, which includes several consumer-facing mobile health apps.
- Source: mobihealthnews
- 496
- November 6, 2017
Company Insight health apps MedHelp Merck
Amgen, Novartis Rev Up for New Alzheimer’s Study

Amgen and Basel, Switzerland-based Novartis announced they have expanded their collaboration with the Banner Alzheimer’s Institute (BAI) to launch a new clinical trial in Alzheimer’s.
- Source: Pharmalive
- 682
- November 6, 2017
Alzheimer's API Clinical Trial Market Views
Shockwave Medical Announces $35 Million in New Financing

Shockwave Medical reported $35 million in new financing, an extension of the company’s previously announced $45 million Series C financing. New investor Fidelity Management & Research Company participated, along with certain funds and accounts advised by T. Rowe Price Associates, Inc., a returning investor.
- Source: Dicardiology
- 621
- November 6, 2017
Peripheral and Coronary Lithoplasty Systems Shockwave Medical
China’s Import and Export Report of Antineoplastic Drugs

Antineoplastic or anticancer drugs, affect the process of cell division i.e. are antiproliferative. They damage the DNA and initiate apoptosis, preventing the development and spread of neoplastic cells. Commonly used antineoplastic drugs can be divided into the following six categories: alkylating agents, anti-metabolites, anticancerous, antibiaties, aminoglutethimide and others. Today, Ddu, the leading global pharmaceutical & medical device B2B online platform, shares China’s Import and Export Report of Antineoplastic Drugs with you. General situation of global market of antineoplastic drugs According to the IMS’s latest report, “Global Oncology Trends 2017” showed that in 2016 the global market sales of antineoplastic drugs were 89.6 billion USD and 85 billion USD in 2015. Over the past five years, the global market of antineoplastic drugs has grown at a compound annual growth rate (CAGR) of 8.7% and is expected to exceed 147 billion USD by 2021. As indicated on the chart, the United States, the European Union and Japan are still the driving ...
- Source: Ddu
- 1,498
- November 3, 2017
anticancer Antineoplastic Market Reports neoplastic cells
Medical Trade Exhibitions in November–Global Product Promotions from the Comfort of Your Own Home!

Since the launch of the Ddu Global Promotion Plan, Ddu has succeeded in helping users do international product promotions without leaving home and has matched thousands of orders, rapidly gaining popularity in the medical trade industry.
- Source: Ddu
- 896
- November 3, 2017
Ddu Global Promotion Plan Exhibitions & Activities trade

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.